for and Thank for quarter fourth our today full you, and you, XXXX us thank update. Grace, joining year business everyone,
at Many milestones. which has call you Directors. a ArQule, development CMO our be today's product Cyclacel clinical joined who joined Merck to by to in when value Chief in by recently delighted on XXXX, acquisition instrumental Brian, the be to and he inflection which key he may time deliver extensive will team as guiding of Brian are our Officer. of Board Dr. He joined We prior has know Medical at was Schwartz, experience,
short. Having CDKX/X part fadraciclib, dose, Phase to XXX-XXX precision potential study. II recently our we to medicine for or or the discovered fadra, progress proof-of-concept recommended approach ready inhibitor, pleased and fadra on report the of II of for a Phase RPXD, are our We determined have the start are
Taken together, deep one fadra. and/or patients function or to our loss that more the with CDKNXA/CDKNXB or suggests including may preclinical MTAP, be hypothesis chromosomal abnormalities, and deletions clinical data including of sensitive
In this I mutational profile patient activity their and selected various tumors we part, solid will evaluate and/or for Phase in lymphoma. cohorts
melanoma, We responses. signals with great abnormalities, which located from will T-cell and initially patient by interest We CDKNXB the including on lymphoma cancer bladder, head need CDKNXA are and which of focus tumors, abnormalities and populations pancreatic mesothelioma, several that identified also certain of cohorts co-deleted. including squamous both activity, endometrial, there occur gene solid are neck, and believe and often melanoma, I in including chromosome X deletions T-cell in hepatobiliary, endometrial, deletions these including industry patient Phase saw on and and CDKNXA esophageal, CDKNXB medical is two and/or glioma, closely lung, we in unmet breast, cholangiocarcinoma, tumors, lung, neck, bladder, several pancreatic including in others. occur lymphomas. solid and squamous, glioma, hepatobiliary, esophageal, head breast, ovarian,
tumor and study Final release, this our the readouts at fadra we types. part. XXX-XXX Phase at meeting, Also later XXXX of upcoming initial in X clinical various data for proof-of-concept key clinical AACR part present for investigators will expect the major activity II from press data escalation a As fadra proof-of-concept the in on, the data year. dose conference mentioned from independent the medical
and fadra discuss our Brian? our review and studies turn to now over will progress plogo clinical the call the I of to some Brian in results.
